ASPG and metabolic dysfunction-associated steatotic liver disease: Our findings provide clear evidence that hepatic ASPG serves as a boost motor for defective insulin signal transduction in the setting of MASLD, highlighting decreasing ASPG expression level as a potential procedure to enhance systemic glucose homeostasis.